Article Type

511 - 525 of 1461 Results       Clear All

New COVID-19 Nasal Spray Therapy Aims to ‟Reduce Viral Load in the Lungs by 100-Fold”

Gladstone in the News December 15, 2021

New COVID-19 Nasal Spray Therapy Aims to ‟Reduce Viral Load in the Lungs by 100-Fold”

abc7 NEWS—Senior Investigator Leor Weinberger, PhD, and Research Investigator Sonali Chaturvedi, PhD, explain their work on a therapy that sharply reduces viral load in the nose of hamsters after a single administration and could add a promising new tool to the therapeutic arsenal against COVID-19.

Gladstone Experts COVID-19 Infectious Disease Weinberger Lab

Blocking an Immune System Molecule in Mice May Help Prevent Long-Term Disabilities after Traumatic Brain Injury

Gladstone in the News December 15, 2021

Blocking an Immune System Molecule in Mice May Help Prevent Long-Term Disabilities after Traumatic Brain Injury

The Conversation—Individuals who survive traumatic brain injury can suffer from life-long complications, such as cognitive deficits, seizures, and sleep disruption. Jeanne Paz, PhD, describes her work in mice showing that treatment with an antibody that blocks an element of immune system activation may be able to prevent such consequences.

Gladstone Experts Traumatic Brain Injury Neurological Disease Paz Lab

Virus-Hijacking COVID-19 Drug from Gladstone Researchers Slows Down Variants, Expects Clinical Trial Early Next Year

Gladstone in the News December 14, 2021

Virus-Hijacking COVID-19 Drug from Gladstone Researchers Slows Down Variants, Expects Clinical Trial Early Next Year

San Francisco Business Times—Senior Investigator Leor Weinberger, PhD, pioneered a new class of antivirals called therapeutic interfering particles (TIPs), which were recently shown to be effective against SARS-CoV-2 in animal models. The approach is now being developed by a startup company and will be headed to clinical trials.

Gladstone Experts COVID-19 Center for Cell Circuitry Infectious Disease Weinberger Lab

How Effective Are Today’s Vaccines against Omicron? Here’s What We Know So Far

Gladstone in the News December 14, 2021

How Effective Are Today’s Vaccines against Omicron? Here’s What We Know So Far

San Francisco Chronicle—The omicron variant of SARS-CoV-2 is spreading rapidly, but it may not be a reason for panic. Nadia Roan explains that our immune system’s cellular response to the vaccines should hold up well against the omicron variant. In addition, Warner Greene predicts that if the variant spreads rapidly but causes just mild disease, it might actually help establish immunity globally, protecting people in places where vaccine access has been limited.

Gladstone Experts COVID-19 Greene Lab Roan Lab

How Severe Is Omicron? Expert Says Variant’s 50 Mutations Could Be Its Downfall

Gladstone in the News December 8, 2021

How Severe Is Omicron? Expert Says Variant’s 50 Mutations Could Be Its Downfall

abc7 News—Senior Investigators Warner Greene, MD, PhD, and Nevan Krogan, PhD, discuss the possibility that Omicron, although more transmissible than previous SARS-CoV-2 variants, may cause less severe disease.

Gladstone Experts COVID-19 Center for HIV Cure Research Data Science and Biotechnology Infectious Disease Greene Lab Krogan Lab

More News

Are You a Journalist Looking to Write about Gladstone?

Explore Info for Media